venBio Partners
Venture capitalSan Francisco · Seed–Late Stage · 8 people tracked
Also known as VENBIO PARTNERS LLC
Investment thesis
venBio invests in life sciences companies developing novel therapeutics for unmet medical needs. The firm seeks teams building treatments with meaningful impact on patient care and works closely with them on development strategy, including intellectual property, chemistry and manufacturing (CMC), and clinical trial design and regulatory considerations. venBio is mindful of potential acquisition partners from the outset, positioning its companies to meet acquirer requirements. Its team's expertise and hands-on involvement aim to help companies make a larger impact and build lasting relationships with the leaders it backs.
Source: firm website, verified Aug 25, 2026.
Team · 8 people
from the firm's website & public directories
What they invest in
from 57 of 80 portfolio companiesBiotech ×55Healthtech ×37Medical Devices ×11AI & Machine Learning ×7Deep Tech ×6Digital Health ×3Longevity ×1New Materials ×1
HQs:United States×43Australia×1United Kingdom×1
Who they back
founder profiles across 17 portfolio companiesFounding team size:solo founder×62 founders×94+ founders×2
Accelerator rootsportfolio companies that came through a program
Investments · 80 tracked
founders shown can be your intro pathBy year:2026 · 22025 · 12024 · 32021 · 22020 · 32018 · 22017 · 22016 · 12015 · 52011 · 122 dated
Harmony Biosciences develops innovative therapeutic treatments focused on rare neurological diseases.
BiotechHealthtechMedical DevicesNorthbrook, US
Jeffrey Aronin(Director)Jeffrey M. Dayno, M.D.(President and Chief Executive Officer)Patrick Morris(Secretary and Treasurer)Robert Repella(Director and Chief Executive Officer)Darien Parhad(Chief Financial Officer)
Board seatAaron Royston· per SEC Form D
Co-investorsAisling CapitalParagon Biosciences LLCValor Equity PartnersVivo Capital
Precision BioSciences develops gene-editing medicines using its proprietary ARCUS genome editing platform, which employs sequence-specific nuclease enzymes to insert, remove, or repair DNA in living cells to treat hard-to-treat conditions including rare genetic diseases and hepatitis B (HBV).
BiotechDeep TechHealthtechDurham, US
JEFF SMITH(Executive Officer)DEREK JANTZ(Executive Officer, Director)MATTHEW KANE(Executive Officer, Director)Jeff Smith(Co-founder)Derek Jantz(Co-founder)TODD MELBY(Executive Officer)
Board seatRobert Adelman· per SEC Form D
Co-investorsage1Aliment CapitalBrace PharmaF-Prime CapitalOCV PartnersOUP (Osage University Partners)+4 more
Achieve Life Sciences is a late-stage specialty pharmaceutical company developing cytisinicline, a treatment for nicotine dependence and smoking cessation.
BiotechHealthtechVancouver, B.C., US
Anthony Clarke(Executive Officer)Richard Stewart(Director)Cindy Jacobs(Executive Officer, Director)Jaime Xinos(Executive Officer)John Bencich(Executive Officer, Director)
BoardBridget Martell(Director)
Co-investorsVivo CapitalFrazier Life Sciences
Alumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases.
AI & Machine LearningBiotechDigital HealthHealthtechLongevitySouth San Francisco, US
Martin Babler(President, Chief Executive Officer and Chairman of the Board)Mark Bradley(Chief Development Officer)Kolbot By(SVP, Head of Technical Operations)Jack Danilkowicz(Chief Commercial Officer)Jörn Drappa(Chief Medical Officer)David M Goldstein(Chief Scientific Officer)
Co-investorsForesite CapitalNextech InvestOrbiMedSamsara BioCapitalSR One Capital ManagementWestlake Village BioPartners+1 more
ALX Oncology is a clinical-stage biopharmaceutical company developing cancer therapies, including its lead candidate evorpacept for immuno-oncology and ALX2004, an antibody-drug conjugate targeting EGFR-positive tumors.
BiotechHealthtech
Co-investorsage1Foresite CapitalLightstone Ventures
Aura Biosciences develops Virus-Like Drug Conjugates (VDCs), a platform using Virus-Like Particles conjugated with drugs or loaded with nucleic acids to target solid tumors.
BiotechHealthtechMedical DevicesCambridge, US
Elisabet de los Pinos, Ph.D.(Executive Officer, Director)Elisabet de los Pinos(Founder)inMichael Wyzga(Executive Officer)Dale Pfost, Ph.D.(Director)Alan E. Walts, Ph.D.(Director)Lewis Geffen(Executive Officer)
Co-investorsAdvent Life SciencesChiesi VenturesDroia VenturesForesite CapitalJazzya InvestmentsMedicxi+4 more
Compass Therapeutics develops antibody-based therapies targeting the tumor microenvironment to treat cancer.
BiotechHealthtechCambridge, US
Co-investorsBioBritF-Prime CapitalForesite CapitalOrbiMedVivo Capital
Johnson & Johnson develops prescription medicines and medical technology across areas including oncology, immunology, neuroscience, cardiopulmonary, cardiovascular, orthopaedics, surgery, and vision.
BiotechHealthtechMedical DevicesNew Brunswick, US
Joaquin Duatoin
Co-investorsAisling CapitalAtlas VentureNaviMed CapitalPortland Seed FundSPRINGROCK VENTURESThe Column Group
Helicons develops a peptide-based therapeutic platform designed to target intracellular proteins previously considered undruggable by combining the specificity of antibodies with the cell-penetrating properties of small molecules.
AI & Machine LearningBiotechDeep TechMedical Devices
Mathai Mammen(CEO, President and Chairman)
Co-investorsARCH Venture PartnersCatalio Capital Management, LPForesite CapitalFrazier Life SciencesGeneral CatalystNextech Invest+5 more
BiotechWaltham, US
Dennis Podlesak(Director)Ivor Royston(Director)John Pallies(Executive Officer)Luke Evnin, Ph.D.(Director)George W Sledge, Jr. M.D.(Director)Fabrice Egros, Ph.D.(Director)
Co-investorsForesite CapitalPappas CapitalSofinnova Ventures
Tenaya Therapeutics is a clinical-stage biotechnology company developing gene therapies for inherited heart diseases, including TN-201 for MYBPC3-associated hypertrophic cardiomyopathy and TN-401 for PKP2-associated arrhythmogenic right ventricular cardiomyopathy.
BiotechHealthtechSouth San Francisco, US
Deepak Srivastava, M.D.(Scientific Founder)Eric Olson, Ph.D.(Scientific Founder)Bruce R. Conklin, M.D.(Scientific Founder)Sheng Ding, Ph.D.(Scientific Founder)Saptarsi Haldar, M.D.(Scientific Founder)Eric Hyllengren(Chief Financial Officer)
Co-investorsGV (Google Ventures)The Column Group
Axonis Therapeutics is a biotechnology company developing small-molecule medicines that target KCC2, a mediator of inhibition in the brain, to treat neurological disorders such as epilepsy and pain.
BiotechDeep TechBoston, US
Shane Hegarty(Executive Officer)Shane V. Hegarty(Chief Scientific Officer & Co-Founder)Jeffrey Imbaro(Executive Officer)Joanna Stanicka(Chief Executive Officer, President & Co-Founder)inJeff Imbaro(Chief Operating Officer)Tiasha Shafiq(Chief of Staff)
Co-investorsMRL Ventures FundSofinnova VenturesCivilization Ventures Management, LlcCreative Destruction Lab (CDL)Hatteras Venture PartnersIaso Ventures+7 more
Eyconis is a clinical-stage biotechnology company developing long-acting ophthalmic therapies for serious eye diseases such as wet age-related macular degeneration and diabetic macular edema using the TransCon technology platform.
BiotechDigital HealthMedical DevicesRedwood City, US
Emmett Cunningham(Executive Officer, Director)Mark Bachleda(Executive Officer, Director)inRobert Vitti(Executive Officer)Oliver Stauch(Executive Officer)inOliver Boris Stauch(Executive Officer)Conrad Wang(Director)
Co-investorsFrazier Life SciencesHealthQuest CapitalvenBio Global Strategic
HealthtechNew York, US
Shawn Leland(Executive Officer, Director)Lori Hu(Director)Michael Caldwell(Director)
BoardSteven Elms(Executive Officer, Director, Promoter)
Board seatRichard Gaster· per SEC Form D · $65M raise · filed Nov 2020
Aeovian Pharmaceuticals is a clinical-stage biopharmaceutical company developing selective small molecule inhibitors to treat rare genetic and age-related diseases caused by dysregulated cellular metabolism.
BiotechBerkeley, US
Allison J. Hulme(CEO & President)John Kincaid(Chief Scientific Officer)Davis Ryman(Executive Officer)Micah Zajic(Executive Officer)Ian Massey(Executive Officer)Stelios Tzannis(Executive Officer, Director)
Board seatRichard Gaster· per SEC Form D
Co-investorsCoastCapCTI Life Sciences Fund L.P.FJ LabsSofinnova VenturesvenBio Global Strategic
South San Francisco, US
Board seatAaron Royston· per SEC Form D · $45.5M raise · filed Dec 2018
Co-investorsAtlas Venture
BiotechDublin 2
Jason Lettman(Director)
Board seatJaume PonsCorey Goodman· per SEC Form D · $36M raise · filed May 2015
NASDAQ-listed company developing therapies for complement cascade-driven diseases in haematology, ophthalmology, and nephrology.
Crestwood, US
Board seatRobert Adelman· per SEC Form D
Co-investorsEMBL VenturesEpidarex Capital
Attralus develops pan-amyloid removal (PAR) therapeutics — biologics and imaging agents designed to bind and remove toxic amyloid — to treat patients with systemic amyloidosis across all disease types and stages.
BiotechHealthtechSouth San Francisco, US
Jonathan Wall(Executive Officer)Spencer Guthrie(Executive Officer)Mark Timney(Executive Officer, Director)Benson Fong(Executive Officer)Rahul Kakkar(Director)Greg Bell(Executive Officer)
Board seatCorey Goodman· per SEC Form D
Co-investorsAlpha Wave GlobalBioBritvenBio Global StrategicVivo Capital
HealthtechSeattle, US
John D. Hoekman(Executive Officer, Director)
BoardMichael Hite(Director)Stewart Parker(Director)
Board seatAaron Royston· per SEC Form D · $37.3M raise · filed Dec 2016
Co-investors5AM VenturesB Capital GroupvenBio Global StrategicWestlake Village BioPartners
San Francisco, US
Board seatAaron Royston· per SEC Form D · $160.4M raise · filed Jun 2024
Co-investorsSofinnova Ventures
BiotechMenlo Park, US
Steven L. Basta(Executive Officer, Director)John Creecy(Director)Scott Whitcup(Director)Ted Ebel(Director)Ketan Patel(Director)David Collier(Director)
Board seatAaron Royston· per SEC Form D · $50.5M raise · filed Jul 2017
San Diego clinical-stage biopharma developing non-bile acid FXR agonists for liver and gastrointestinal diseases.
BiotechSan Diego, US
Ronald Evans(Director)Trisha Millican(Executive Officer)Ken Song(Executive Officer, Director)
BoardKristina Burow(Director)inRichard Heyman(Director)inAmir Nashat(Director)in
Board seatRobert Adelman· per SEC Form D · $37.8M raise · filed Nov 2016
Co-investorsage1EcoR1 CapitalLAVLilly Asia VenturesNew Enterprise Associates (NEA)Vivo Capital+2 more
RayzeBio develops radiopharmaceutical therapies for cancer treatment.
BiotechHealthtechMedical DevicesSan Diego, US
Ken Song(Executive Officer, Director)Ben Hickey(President)Abhi Bhat, PhD(Senior Vice President, Research & Development)Deborah Charych(Executive Officer)Yi Larson(Director)
Board seatAaron Royston· per SEC Form D
Co-investorsSamsara BioCapitalScion Life SciencesSofinnova VenturesTCG CrossoverVersant VenturesVivo Capital+1 more
BiotechSan Francisco, US
Curt Bradshaw(Executive Officer, Director, Promoter)Frank Muhlenbeck(Mr. Muhlenbeck is a Manager of the Issuer.)Louis Tartaglia(Mr. Tartaglia is a Manager of the Issuer.)
BoardCorey Goodman(Executive Officer, Director, Promoter)inSteven Dowdy(Director)
Board seatRobert Adelman· per SEC Form D · $4M raise · filed Dec 2015
Tallac Therapeutics is a biopharmaceutical company developing oligonucleotide-based antibody drug conjugates (ADCs) to treat cancer, including its Toll-like Receptor Agonist Antibody Conjugates (TRAAC) that deliver a TLR9 agonist to activate immune responses within the tumor microenvironment.
BiotechHealthtechBurlingame, US
Board seatJaume PonsCorey Goodman· per SEC Form D
Co-investorsLightstone VenturesMRL Ventures FundMatrix Partners ChinavenBio Global Strategic
BiotechSan Diego, US
Jingrong Jean Cui(Executive Officer, Director)Yishan Li(Executive Officer, Director)Jingrong Cui(Executive Officer, Director)
BoardGeorge J. Lee(Director)Kenneth Fong(Director)Bihua Chen(Director)
Board seatRobert Adelman· per SEC Form D · $80M raise · filed Oct 2018
35Pharma is a biopharmaceutical company that designs and develops ligand traps targeting the Activin x GDF signaling pathway to treat pulmonary hypertension, heart failure, and obesity.
BiotechHealthtech
Co-investorsFrazier Life SciencesJanus Henderson InvestorsVivo Capital
AI & Machine LearningBiotechDigital HealthHealthtech
Co-investorsDecheng CapitalSamsara BioCapital
Akero develops engineered protein therapies for metabolic diseases, particularly MASH (metabolic dysfunction-associated steatohepatitis) and other conditions with high unmet medical need.
BiotechHealthtechMedical Devices
Co-investorsAtlas VentureForesite CapitalFrazier Life SciencesScion Life SciencesThe Innovation SpaceVersant Ventures
Alexion is a biopharmaceutical company focused on research and development of treatments for rare diseases, serving rare disease patients and their families worldwide.
BiotechHealthtechBoston, US
Co-investorsAndera PartnersConnecticut Innovations
Co-investorsAvoro Capital AdvisorsEpidarex CapitalF-Prime CapitalKeyhorse CapitalSofinnova VenturesSolasta Ventures
Arpeggio Bio develops pharmaceutical drugs that target transcription factors using artificial intelligence and RNA-sequencing technology, with lead programs in development for melanoma treatment and rare disease applications.
BiotechHealthtechBoulder, US
Joey Azofeifa(Founder)inJoseph G. Azofeifa(Executive Officer, Director)Laura Norris(Executive Officer, Director)Timothy Read(Executive Officer, Director)Eric Martin(Executive Officer)
BoardAmit Mehta(Director)
Co-investorsFifty YearsFundersClubTau VenturesY CombinatorBoxOne VenturesvenBio Global Strategic+1 more
Arrakis Therapeutics develops RNA-targeted small-molecule (rSM) medicines, working independently and with partners to create drug candidates aimed at the root causes of disease.
AI & Machine LearningBiotechDeep TechHealthtechCambridge, US
Michael Gilman(Executive Officer, Director)Mark DeLong(CEO)David Neafus(Executive Officer)Russell C. Petter(Executive Officer)
BoardColleen Cuffaro(Director)inAlan E. Walts(Director)in
Co-investorsCanaan PartnersPfizer VenturesAdvent Life SciencesNextech InvestOUP (Osage University Partners)Pfizer Venture Investments+1 more
Artiva Biotherapeutics is a clinical-stage biotechnology company developing natural killer (NK) cell-based therapies for patients with autoimmune diseases.
BiotechHealthtechSan Diego, US
Co-investors5AM VenturesEcoR1 CapitalRA CapitalvenBio Global Strategic
BiotechSan Francisco, US
Matthew Patterson(Executive Officer, Director)
BoardJonathan Silverstein(Director)inSteve Squinto(Director)inKush Parmar(Director)Jonathan Leff(Director)Thomas Woiwode(Director)
Co-investorsAsset Management CompanyRA CapitalDeerfield Management CompanyOrbiMedVenrock
BiotechVictoria
Kurt von Emster(Director)Benjamin Rovinski(Director)Chris Kim(Director)Donald Wyatt(Director)Stephen W. Zaruby(Executive Officer, Director)Michael Martin(Executive Officer, Director)
Co-investorsLumira VenturesNew Enterprise Associates (NEA)
BiotechLa Jolla, US
David A. Stamler(Executive Officer)Sepehr Sarshar(Director)Andreas Sommer(Executive Officer)David Collier(Director)Pratik Shah(Director)Samuel Saks(Director)
Co-investorsThomas, McNerney & Partners
Axent Biosciences develops cell therapies using engineered, fully synthetic biocompatible biomaterials that create protective environments for cells.
BiotechHealthtechNew Materials
BiotechCambridge, US
Praveen Tipirneni(Executive Officer, Director)
BoardMichelle Doig(Director)inAaron Royston(Director)Michael Gladstone(Director)inXiaodi Su(Director)
Co-investorsAtlas VentureBain Capital Life SciencesJanus Henderson InvestorsLAVOmega FundsvenBio Global Strategic+1 more
Caldera is a clinical-stage biotechnology company developing CLD-423, a bispecific antibody targeting the IL-23p19 and TL1A pathways for inflammatory bowel disease and other immunologic and inflammatory diseases.
BiotechHealthtech
Praveen Tipirneni(Chief Executive Officer)Liangsu Wang(Chief Scientific Officer)Zhong Liu(Chief Technology Officer)Aaron Pelta(Chief Business Officer)Colm White(Chief Program Officer)
Co-investorsAtlas VentureJanus Henderson InvestorsLAV
CandidRx develops T-cell engager antibodies to treat autoimmune diseases by redirecting T-cells to eliminate autoreactive B-cells.
BiotechHealthtechSan Diego, US
Ken Song(Chairman, President and CEO)Kenneth Song, M.D.(Executive Officer, Director)Arvind Kush(Executive Officer)Timothy Lu, M.D.(Executive Officer)Bernie Huyghe, Ph.D.(Executive Officer)
BoardJeffrey Tong, Ph.D.(Director)
Co-investorsForesite CapitalOrbiMedSamsara BioCapitalTCG CrossoverThird Rock VenturesVida Ventures
Entact is a drug discovery company developing treatments for patients.
BiotechDeep TechWatertown, US
Victoria Richon(Executive Officer, Director, Promoter)Ruben Tommasi(Chief Scientific Officer)Michael Gutch(Chief Operating Officer)Alon Lazarus(Director)
BoardAndrew Sinclair(Director)Anna French(Director)
Co-investorsvenBio Global Strategic
BiotechWoburn, US
David Lucchino(Executive Officer, Director)Christopher R. Loose(Executive Officer)
BoardRobert Langer(Director)Marc Kozin(Director)Marc Cohen(Director)Timothy Barberich(Director)
Co-investorsAlexandriaKendall Capital Partners
Bristol Myers Squibb is a biopharmaceutical company that develops and delivers medicines across oncology, hematology, neuroscience, immunology, and cardiovascular disease areas.
BiotechHealthtechMedical DevicesNew York, US
Co-investorsKleiner PerkinsNew Enterprise Associates (NEA)Nextech InvestProspect Venture PartnersRho Capital PartnersRho Ventures+2 more
HistoWiz provides digital pathology services including precision histology, immunostaining, slide archiving, and AI-powered image analysis for research and clinical laboratories.
AI & Machine LearningBiotechHealthtechMedical DevicesNew York City, US
Ke Cheng(Founder/CEO)inLinh Hoang(Chief Executive Officer)Jerry Kuang(Chief Operations Officer)Julie Feldstein(Chief Pathologist)
Co-investorsVivo CapitalY Combinator
Impel Pharmaceuticals develops therapies for patients using its drug delivery technology and expertise with small and large molecules.
BiotechHealthtechMedical Devices
Co-investorsCowles VenturesNorwest Venture Partners
Insamo develops an automated platform for drug discovery that designs, synthesizes, and tests cyclic peptides at scale using machine learning and proprietary experimental data.
AI & Machine LearningBiotechDeep TechChippendale, AU
TIMOTHY CRAVEN(Executive Officer, Director)TOBY PASSIOURA(Executive Officer, Director)Tim Craven(CEO)Toby Passioura(CSO)Glen McIntyre(COO)GLEN MCINTYRE(Executive Officer, Director)
Co-investorsCivilization Ventures Management, LlcMRL Ventures FundPlayground GlobalAxial VCvenBio Global Strategic
Lyell is a clinical-stage biotech developing next-generation CAR T-cell product candidates intended as one-time treatments for patients with cancer, targeting both hematologic malignancies and solid tumors.
BiotechHealthtech
Co-investorsARCH Venture PartnersForesite Capital8VCAxial VC
Co-investorsAlpha Wave GlobalSofinnova Ventures
Neurogastrx is a late clinical-stage biopharmaceutical company developing therapies for patients with serious gastrointestinal (GI) disorders that have limited treatment options.
BiotechHealthtechWoburn, US
Cyril De Colle(Founder)in
Co-investors5AM VenturesOrbiMedSamsara BioCapitalVivo CapitalvenBio Global StrategicWestlake Village BioPartners
NFlection is a clinical-stage biopharmaceutical company developing topical first-in-class MEK inhibitors for RAS-mediated disorders.
BiotechMedical DevicesBoston, US
Co-investorsF-Prime CapitalvenBio Global Strategic
NorthSea Therapeutics is a late-stage clinical biotechnology company developing structurally engineered fatty acids (SEFAs) as oral treatments for metabolic, cholestatic, and fibrotic diseases.
BiotechHealthtech
Co-investorsNew Science VenturesYsios CapitalSofinnova Ventures
Oak Hill Bio is a clinical-stage biotechnology company that acquires and develops late-stage rare disease drugs deprioritized by larger pharmaceutical companies.
BiotechHealthtech
Pharvaris develops investigational oral therapies for people living with bradykinin-mediated angioedema.
BiotechHealthtech
Co-investorsBain Capital Life SciencesForesite CapitalKurma Partners
Portage Biotech is a clinical-stage immuno-oncology company developing first-in-class cancer therapies that target checkpoint resistance pathways.
BiotechHealthtech
Regeneron is a biotechnology company that develops medicines ranging from biologics to genetic medicines to treat serious diseases across areas such as metabolic disease, ophthalmology, and rare disease.
BiotechHealthtechTarrytown, US
Co-investorsRidgeback CapitalSanderling VenturesWireframe Ventures
Co-investorsBoutique Venture PartnersOUP (Osage University Partners)
Clinical-stage biotech expanding the genetic alphabet with synthetic nucleotides; acquired by Sanofi for $2.5B in 2020.
BiotechLa Jolla, US
Jay Lichter(Director)Douglas Downs(Executive Officer)Floyd Romesberg(Director)Court Turner(Executive Officer, Director)
Co-investorsAvalon BioVenturesBoutique Venture PartnersCorrelation VenturesOUP (Osage University Partners)RA Capital
Teva Pharmaceuticals is a biopharmaceutical company that develops innovative medicines across therapeutic areas such as neuroscience and immunology, alongside a large generics and biosimilars business.
BiotechHealthtech
Co-investorsBlumberg Capital
San Diego, US
Mark S. Forman(Executive Officer)Matthew Moore(Executive Officer)John Nuss(Executive Officer)Jigar Choksey(Director)Martin Auster(Executive Officer)Christopher W. Krueger(Executive Officer)
Co-investorsNew Science VenturesThird Point VenturesSilverArc PrivatevenBio Global Strategic
Verona Pharma develops treatments for chronic lung conditions.
BiotechHealthtechLondon
Jan-Anders Karlsson(Executive Officer, Director)Peter Spargo(Executive Officer)Patrick Humphrey(Director)Ken Cunningham(Director)Kenneth Newman(Executive Officer)Anders Ullman(Director)
Co-investorsAccess BiotechnologyAisling CapitalAndera PartnersForesite CapitalFrazier Life SciencesNew Enterprise Associates (NEA)+4 more
Cambridge, MA biotech developing single-course in vivo base editing medicines to permanently lower cardiovascular disease risk.
BiotechCambridge, US
Andrew Ashe(Executive Officer)Sekar Kathiresan(Executive Officer, Director)Andrew Bellinger(Executive Officer)
BoardJohn Evans(Director)Anthony Philippakis(Director)inKrishna Yeshwant(Director)in
Co-investorsARCH Venture PartnersF-Prime CapitalGV (Google Ventures)RA CapitalForesite Capital
AI & Machine LearningBiotechHealthtech
Co-investorsAvoro Capital AdvisorsMedicxiTCG CrossoverUniQuest Extension Fund (UEF)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 17
IPOs and acquisitions across the tracked portfolioHarmony BiosciencesNASDAQ: HRMYPrecision BioSciencesNASDAQ: DTILAchieve Life SciencesNASDAQ: ACHVAlumisNASDAQ: ALMSAlumniNYSE: AZNAlx OncologyNASDAQ: ALXOAura BiosciencesNASDAQ: AURACompass TherapeuticsNASDAQ: CMPXData I/ONASDAQ: DAIOImmuronNASDAQ: IMRNJohnson & JohnsonNYSE: JNJParabilis MedicinesNASDAQ: PBLSSyndax PharmaceuticalsNASDAQ: SNDXTenaya TherapeuticsNASDAQ: TNYAAcelyrinacq. by AlumisSynthorxacq. by SanofiVicebioacq. by Sanofi
Portfolio news
latest coverage across their companiesTeva · marketbeat.com · Aug 23, 2026
Alx Oncology · investing.com · Aug 18, 2026
Aura Biosciences · tickerreport.com · Aug 18, 2026
Tenaya Therapeutics · investing.com · Aug 18, 2026
Compass Therapeutics · simplywall.st · Aug 14, 2026
Alumis · stocktitan.net · Aug 13, 2026
Syndax Pharmaceuticals · aol.com · Aug 12, 2026
Achieve Life Sciences · stocktitan.net · Aug 11, 2026
Frequently asked questions
- How many investments has venBio Partners made?
- venBio Partners has 69 tracked investments, 5 of which have exited via acquisition or IPO, including 3 dated in the last 24 months.
- What stage does venBio Partners invest at?
- venBio Partners invests at the Seed, Series A, Series B, Series C, Late Stage stages.
- What sectors does venBio Partners focus on?
- venBio Partners focuses on Biotech, Healthtech, Medical Devices.
- Where is venBio Partners located?
- venBio Partners is headquartered in San Francisco, US.
- Does venBio Partners lead rounds?
- venBio Partners typically participates in rounds rather than leading them.
- Who does venBio Partners co-invest with?
- venBio Partners most often shares deals with Foresite Capital, Vivo Capital, RA Capital, among 99 tracked co-investors.
Co-investors · 36
Foresite Capital is a healthcare-focused investment firm backing companies at the intersection of technology and biotechnology to personalize healthcare and accelerate medical innovation.
Vivo Capital is a global healthcare-focused investment firm operating a multi-strategy platform spanning venture capital, private equity, and public equity. It aims to expand healthcare access and drive innovation through its 'Ecosystem Strategy.'
Sofinnova is an investment firm focused on the life sciences and biotechnology sector, partnering with companies from inception through drug development, regulatory approval, company building, and IPO.
OrbiMed is a global healthcare-focused investment firm providing financing and operational support to companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
RA Capital is a multi-stage investment firm focused on healthcare, life sciences, and planetary health, investing across public and private markets and creating new companies through its Raven incubation platform.
Atlas Venture is a life sciences venture capital firm with three decades of experience investing in and building biotech and medical innovation companies, including startups launched from its own incubator.
Samsara BioCapital is an investment firm backing the development of transformative therapeutics for patients, bringing together scientists, physicians, drug developers, and business leaders to support next-generation therapeutic breakthroughs.
New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.
Nextech Invest is a Zurich-based investment firm focused on emerging biotechnology companies, backing transformative cancer medicines and precision medicine advances worldwide.
Westlake Village BioPartners is a Los Angeles-based life science venture capital firm that builds and incubates biotech companies around top entrepreneurs, providing hands-on support from ideation through clinical and commercial stages.
5AM Ventures is a life science venture capital firm founded in 2002 that invests primarily in private therapeutic companies, with a focus on biopharmaceuticals, drug delivery technologies, and life science instruments.
GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.
▶24 more co-investors
Versant VenturesGeneral CatalystKleiner PerkinsCanaan PartnersVenrockPlayground GlobalThird Rock VenturesAbingworthOmega FundsLilly Asia VenturesUberEclipse VenturesGeneral AtlanticHouseMorgenthalerAccess IndustriesApollo Health VenturesCofounders CapitalSeroba Life Sciences4BIO CapitalRunway Growth CapitalKohFoundersMohr Davidow VenturesLuma Group
Firms observed investing alongside venBio Partners, from public investor directories. Shared companies are the overlap with venBio Partners's recorded portfolio.
Similar investors
Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.
Pappas Capital is a life sciences venture capital firm that invests in and helps build companies developing next-generation life science products and technologies.
Korea Investment Partners is a South Korea-based venture capital firm that invests across multiple stages from early-stage startups through growth and buyout transactions, including venture debt and mezzanine financing. The firm operates across venture capital, middle market, and growth equity investment categories.
JSTAR Capital Investments is a healthcare-focused investment firm backing medical technology companies, providing capital and expert guidance to advance patient care and address global healthcare challenges.
New Science Ventures (NSV) is a venture capital firm based in Connecticut and London that backs companies applying novel scientific approaches in the life sciences and information technology sectors.